Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on the discovery and advancement of small molecule therapies designed to treat a range of cancers. The company's pipeline features two primary drug candidates: ZN-c3, an inhibitor of the WEE1 protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. ZN-c3 is currently undergoing various trials, including a Phase 2 study for advanced solid tumors, a Phase 1/2 trial for advanced solid tumors when administered as a monotherapy, and an ongoing Phase 1b trial in conjunction with chemotherapy for patients suffering from platinum-resistant ovarian cancer. Additionally, it is being investigated in a Phase 2 monotherapy trial focused on a tumor-agnostic predictive biomarker. ZN-c5 is in a Phase 1/2 clinical trial aimed at advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced/metastatic breast cancer. Beyond these, Zentalis is developing ZN-d5, a selective B-cell lymphoma 2 inhibitor in Phase 1 clinical trials for non-Hodgkin's lymphoma and acute myelogenous leukemia, and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in a Phase 1/2 clinical study for advanced non-small cell lung cancer. The company is also innovating BCL-xL heterobifunctional degraders, specifically designed to utilize E3 ligases not present in platelets, thereby mitigating the dose-limiting thrombocytopenia typically associated with other BCL-xL inhibitors. Incorporated in 2014 and based in New York, New York, Zentalis Pharmaceuticals, Inc. has established licensing agreements and strategic collaborations with partners such as Recurium IP Holdings, LLC, Mayo Foundation for Medical Education and Research, SciClone Pharmaceuticals International (Cayman) Development Ltd., Pfizer, Inc., Eli Lilly and Company, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

CEO: Julie Eastland - https://zentalis.com